There is strong evidence that medical researchers’ financial ties to their industry funders may directly influence their published positions in supporting the benefit or downplaying the harm of the products they are “studying”.
For example, there is often a demonstrated difference between internal drug company documents about the research trial results that they fund, and the articles reporting that research that end up in the medical journals that your doctor reads. The New England Journal of Medicine has referred to this practice as ‘selective outcome reporting’.
But for the sake of clarity, let’s just call it ‘lying’. Continue reading